<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534608</url>
  </required_header>
  <id_info>
    <org_study_id>PV7336</org_study_id>
    <nct_id>NCT04534608</nct_id>
  </id_info>
  <brief_title>COVID-19 Child Health Investigation of Latent Disease in Hamburg</brief_title>
  <acronym>C19CHILD</acronym>
  <official_title>Prevalence of Infection and Seroconversion and the Clinical Course of the Novel Coronavirus SARS-CoV-2 Infection in Children Between 0 to 18 Years of Age in Hamburg and Surroundings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Altona Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wilhelmstift Children´s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helios Mariahilf Klinik Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asklepios Klinik Nord - Heidberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study measures infection rates and the presence of antibodies for SARS-CoV-2 (COVID-19)
      among in- and outpatients of all pediatric hospitals, as well as volunteers aged 0 to 18
      years in Hamburg, Germany. Participants with a positive nasopharyngeal swab PCR or a positive
      antibody test enter the Follow-up phase of 6 months. The follow up includes a PCR and
      antibody testing of all household contacts at 0, 3 and 6 months, as well as laboratory
      testing of children to identify immunological, metabolic and genetic risk factors for
      infection and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into a Screening phase and a Follow-up phase. In the Screening phase, an
      obligatory polymerase chain reaction (PCR) in the nasopharyngeal swab and an optional serum
      antibody testing are carried out for severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2). An obligatory standardized questionnaire is used to evaluate symptoms and
      contacts, medical history and underlying conditions and the psychological effects of the
      Coronavirus disease 2019 (COVID-19) pandemic, as well as its effects on individual access to
      medical care. Children with a positive nasopharyngeal swab or antibody test, as well as their
      household contacts aged 0 to 18 years enter the Follow-up phase. During the Follow-up phase,
      blood and urine samples are taken from children for immunological analysis, HLA typing and
      untargeted metabolomics, enabling a broad analysis of the adaptive and innate immune response
      to SARS-CoV-2, as well as metabolic and genetic risk factors for infection and disease
      compared to age and sex-matched healthy controls. Furthermore, a repeated swab and antibody
      testing at 0, 3 and 6 months for children and adult household contacts is carried out to
      analyse household transmission of SARS-CoV-2 in children and adults and the persistence of
      antibodies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute infection by SARS-CoV-2</measure>
    <time_frame>6 weeks</time_frame>
    <description>Detection of SARS-CoV-2 by PCR in the nasopharyngeal swab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion for SARS-CoV-2</measure>
    <time_frame>6 months</time_frame>
    <description>Detection of antibodies against SARS-CoV-2 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune phenotyping</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of the innate and adaptive immune system by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA Typing</measure>
    <time_frame>6 months</time_frame>
    <description>HLA typing by sequencing to identify protective- and risk constellations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matabolomics</measure>
    <time_frame>6 months</time_frame>
    <description>Untargeted metabolomics in urine and plasma</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">6000</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Asymptomatic children w/out an underlying condition</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic children with underlying condition(s)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Children with COVID-19 symptoms w/out an underlying condition</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Children with COVID-19 symptoms with underlying condition(s)</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. In- and outpatients aged 0 to 18 years of all pediatric hospitals in Hamburg, Germany

          2. Healthy children aged 0 to 18 years as volunteers

          3. Participants of other studies or their children (Prenatal Investigation of Children's
             Health - PRINCE Study, Hamburg City Health Study)

          4. Children, who are household contacts of SARS-CoV-2 positive study participants will
             directly enter the Follow-up phase

        Healthy Control Group:

        A group of children tested negative for SARS-CoV-2 by PCR and antibody testing will be
        included as control group for the immunologic, metabolic and genetic follow up. This group
        is recruited from participants in group 2 and 3 (above).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children or Teenagers aged 0-18 years

          -  Patient in one of the participating centers or volunteer in the central C19.CHILD
             Study Clinic

          -  Informed consent from parents or guardians.

          -  Informed consent from children &gt;7 years (unless not capable)

        Exclusion Criteria:

          -  Prematurity &lt;37 weeks of gestation

          -  Informed consent of parents and guardians not possible in spoken word or otherwise

          -  Informed consent not given
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ania C Muntau, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soeren W Gersting, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Mir, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.c19child.hamburg</url>
    <description>Study Homepage</description>
  </link>
  <link>
    <url>https://www.uke.de/kliniken-institute/kliniken/kinder-und-jugendmedizin/index.html</url>
    <description>Universitätsklinikum Hamburg-Eppendorf, Department of Pediatrics Homepage</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Ania C. Muntau</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>children</keyword>
  <keyword>observational</keyword>
  <keyword>antibody</keyword>
  <keyword>PCR</keyword>
  <keyword>immunology</keyword>
  <keyword>metabolomics</keyword>
  <keyword>household</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

